|
000
| 01499nam 2200289za 4500 |
|---|
| 001 | 9.848020 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153557 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171129s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660240497|z9780660240503 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-184/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aBiomanufacturing |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c2018. |
|---|
| 300 | |a[2] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Biofabrication. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"January 2018." |
|---|
| 520 | |a"The NRC helps biotechs produce their biologics and vaccines, from bench to pilot scale. Our teams can produce thousands of protein variants per year for high-throughput screening. Once a lead is selected, we develop custom clones and processes, scale them up in our pilot plants, purify and analyze the material, and provide documentation and quality assurance. We transfer our expression systems, processes and analytics to cGMP-certified manufacturers to stimulate a strong biomanufacturing sector in Canada"--P. [1]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aPharmaceutical biotechnology |
|---|
| 775 | 08|tBiofabrication |w(CaOODSP)9.848025 |
|---|
| 776 | 0#|tBiomanufacturing |w(CaOODSP)9.848024 |
|---|
| 856 | 40|qPDF|s123 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-184-2017-eng.pdf |
|---|